SYRE supply chain intelligence for Spyre Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Spyre Therapeutics, Inc. (SYRE) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| EVERCORE-GROUP-L-L-C | EVERCORE-GROUP-L-L-C | 92% | On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. an… |
| GOLDMAN-SACHS-CO-LLC | GOLDMAN-SACHS-CO-LLC | 92% | On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. an… |
| GUGGENHEIM-SECURITIES-LLC | GUGGENHEIM-SECURITIES-LLC | 92% | On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. an… |
| JEFFERIES-LLC | JEFFERIES-LLC | 92% | On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. an… |
| PARAGON-THERAPEUTICS-INC | PARAGON-THERAPEUTICS-INC | 92% | On May 14, 2024, the Company and Paragon entered into (i) a license agreement (the “SPY001 License Agreement”), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive … |
| WUXI-BIOLOGICS-HONG-KONG-LIMITED | WUXI-BIOLOGICS-HONG-KONG-LIMITED | 92% | Pursuant to a Novation Agreement dated September 19, 2023, by and between us, Paragon and WuXi Biologics, we novated (i) a Biologics Master Services Agreement and (ii) a Cell Line License Agreement. |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from JNJ grap… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SYRE graph: Reciprocal relationship from SNYN… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JNJ | Johnson & Johnson | 72% | uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from SYRE graph: uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them… |
| SNYNF | Sanofi | 72% | uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from SYRE graph: uld any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize th… |
| AEGLEA-BIOTHERAPEUTICS-HOLDINGS-LLC | AEGLEA-BIOTHERAPEUTICS-HOLDINGS-LLC | 62% | quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| AEGLEA-BIOTHERAPEUTICS-INC | AEGLEA-BIOTHERAPEUTICS-INC | 62% | ubjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by commu… |
| ASPEN-MERGER-SUB-I-INC | ASPEN-MERGER-SUB-I-INC | 62% | quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| COMPANY-SEQUOIA-MERGER-SUB-II-LLC | COMPANY-SEQUOIA-MERGER-SUB-II-LLC | 62% | quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| EQUINITI-TRUST-COMPANY-LLC | EQUINITI-TRUST-COMPANY-LLC | 62% | ial materials, study monitoring and data analysis that could materially adversely impact our business, results of operations and overall financial performance in future periods. As of the filing date… |
| EU-CLINICAL-TRIALS-EXPERT-GROUP | EU-CLINICAL-TRIALS-EXPERT-GROUP | 62% | quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| LIMITED-LIABILITY-COMPANY | LIMITED-LIABILITY-COMPANY | 62% | quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initia… |
| PRESENTATION-SPYRE-THERAPEUTICS-INC | PRESENTATION-SPYRE-THERAPEUTICS-INC | 62% | ubjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by commu… |
| TRUST-COMPANY-LLC | TRUST-COMPANY-LLC | 62% | ial materials, study monitoring and data analysis that could materially adversely impact our business, results of operations and overall financial performance in future periods. As of the filing date… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SYRE-DEBT-12861 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| SYRE-DEBT-12860 | Warrants outstanding: 694892 | 90% | xbrl warrant detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SYRE-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 199 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |